Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Aug;6(2):295-305.
doi: 10.3892/ol.2013.1405. Epub 2013 Jun 17.

Endocrine resistance in breast cancer: Current status and a perspective on the roles of miRNAs (Review)

Jichun Zhou  1 , Rongyue Teng, Qinchuan Wang, Chenpu Xu, Jufeng Guo, Chao Yuan, Jianguo Shen, Wenxian Hu, Linbo Wang, Shuduo Xie
Affiliations

Endocrine resistance in breast cancer: Current status and a perspective on the roles of miRNAs (Review)

Jichun Zhou et al. Oncol Lett. 2013 Aug.

Abstract

Current endocrine therapies for females with estrogen receptor-positive breast cancer have facilitated substantial improvements in outcomes. The effectiveness of endocrine therapy is limited by either initial de novo resistance or acquired endocrine resistance. Multiple mechanisms responsible for endocrine resistance have been proposed, including deregulation of various components of the estrogen receptor (ER) pathway, alterations in cell cycle and cell survival signaling molecules, and the activation of escape pathways. Dysregulation of miRNA expression has been associated with experimental and clinical endocrine therapy resistance. miRNAs are pivotal to understanding the complex biological mechanism of endocrine resistance, and may serve as novel candidate predictive and prognostic surrogates and therapeutic targets. This review focuses on current progress concerning the roles of miRNAs in endocrine resistance, and discusses the challenges and opportunities for implementing miRNA-based assays and treatment for patients with endocrine-resistant breast cancer.

Keywords: breast cancer; endocrine resistance; miRNAs.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Typical model of investigation on the role of miRNAs in endocrine resistance in breast cancer.
Figure 2.
Figure 2.
An overview of the interaction between ER and miRNAs. ER, estrogen receptor.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Tamoxifen for early breast cancer: an overview of the randomized trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet. 1998;351:1451–1467. No authors listed: - PubMed
    1. Lau NC, Lim LP, Weinstein EG, Bartel DP. An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans. Science. 2001;294:858–862. - PubMed
    1. Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T. Identification of novel genes coding for small expressed RNAs. Science. 2001;294:853–858. - PubMed
    1. Lee RC, Ambros V. An extensive class of small RNAs in Caenorhabditis elegans. Science. 2001;294:862–864. - PubMed
    1. Ambros V. The functions of animal microRNAs. Nature. 2004;431:350–355. - PubMed

LinkOut - more resources